Net profit jumped 77% to US$2.53 billion in the third quarter (Q3) compared with the July-September period one year earlier, AstraZeneca said in a statement.

“We are… delivering on our strategy to strengthen our operations in the US to power our growth,” said chief executive Pascal Soriot.

“This includes a historic agreement with the US government to lower the cost of medicines for American patients, and broadening our US manufacturing footprint,” Soriot said.

Trump last month announced a deal with AstraZeneca for significantly lower drug prices in the US.

In exchange, the Trump administration agreed to a three-year delay on new tariffs.

Meanwhile in July, AstraZeneca announced plans to invest US$50 billion by 2030 on boosting its US manufacturing and research operations.

At the end of September, it said it planned to list its shares directly on the New York Stock Exchange to attract more investors.

Britain’s largest drugmaker will remain headquartered in the UK and keep its primary listing on London’s top-tier FTSE 100 index.

However, the move highlights the increasing importance of the US market to AstraZeneca, which today added that group revenue grew 12% to US$15.2 billion in Q3, driven by oncology drugs.